JLE

Hépato-Gastro & Oncologie Digestive

MENU

La polypose gastrique : diagnostic et prise en charge Volume 25, numéro 1, Janvier 2018

  • [1] Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours. Vol. 3. Lyon : IARC ; 1999. 417 p.
  • [2] Carmack SW, Genta RM, Schuler CM, et al. The current spectrum of gastric polyps : a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009 ; 104 : 1524-32.
  • [3] Rozas D.A., Rackoff A.I., Brady P.G. Hyperplastic gastric polyposis : a rare entity. Clin Gastroenterol Hepatol. 2010;8:e85.
  • [4] Scoazec J.-Y. Polypes gastriques : pathologie et génétiques. Ann Pathol. 2006;26:173-199.
  • [5] Freeman H.J., Kwan P.W.C., Gray J.R. Hyperplastic gastric polyposis complicated by a high-grade sarcomatoid malignancy. Can J Gastroenterol Hepatol. 2014;28:239-240.
  • [6] Heresbach D, Napoléon B, Delchier J-C, et al. Consensus en Endoscopie Digestive (CED). Acta Endosc 2009 ; 39 : 206-11.
  • [7] Genta RM, Schuler CM, Robiou CI, et al. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin Gastroenterol Hepatol 2009 ; 7 : 849-54.
  • [8] Burt R.W. Gastric fundic gland polyps. Gastroenterology. 2003;125:1462-1469.
  • [9] Sekine S., Shibata T., Yamauchi Y. Beta-catenin mutations in sporadic fundic gland polyps. Virchows Arch Int J Pathol. 2002;440:381-386.
  • [10] Jalving M., Koornstra J.J., Wesseling J. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341-1348.
  • [11] Freeman H.J. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol WJG. 2008;14:1318-1320.
  • [12] Fossmark R., Jianu C.S., Martinsen T.C. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol. 2008;43:20-24.
  • [13] Kim J.-S., Chae H.S., Kim H.-K. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with omeprazole. Korean J Gastroenterol Taehan Sohwagi Hakhoe Chi. 2008;51:305-308.
  • [14] Raghunath A.S., O’Morain C., McLoughlin R.C. Review article : the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22:55-63. Suppl. 1
  • [15] Domizio P., Talbot I.C., Spigelman A.D. Upper gastrointestinal pathology in familial adenomatous polyposis : results from a prospective study of 102 patients. J Clin Pathol. 1990;43:738-743.
  • [16] Bianchi L.K., Burke C.A., Bennett A.E. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008;6:180-185.
  • [17] Jagelman D.G., DeCosse J.J., Bussey H.J. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet. 1988;1:1149-1151.
  • [18] Syngal S, Brand RE, Church JM, et al. ACG Clinical Guideline : Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. Am J Gastroenterol 2015 ; 110 : 223-63.
  • [19] Islam R.S., Patel N.C., Lam-Himlin D. Gastric polyps : a review of clinical, endoscopic, and histopathologic features and management decisions. Gastroenterol Hepatol. 2013;9:640-651.
  • [20] Jung I., Gurzu S., Turdean G.S. Current status of familial gastrointestinal polyposis syndromes. World J Gastrointest Oncol. 2015;7:347-355.
  • [21] Lam-Himlin D., Park J.Y., Cornish T.C. Morphologic characterization of syndromic gastric polyps. Am J Surg Pathol. 2010;34:1656-1662.
  • [22] Vyas M., Yang X., Zhang X. Gastric Hamartomatous Polyps—Review and Update. Clin Med Insights Gastroenterol. 2016;9:3-10.
  • [23] Pintiliciuc O.G., Heresbach D., de-Lajarte-Thirouard A.-S. Gastric involvement in juvenile polyposis associated with germline SMAD4 mutations : an entity characterized by a mixed hypertrophic and polypoid gastropathy. Gastroenterol Clin Biol. 2008;32:445-450.
  • [24] Aretz S., Stienen D., Uhlhaas S. High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. J Med Genet. 2007;44:702-709.
  • [25] Nelen M.R., Kremer H., Konings I.B. Novel PTEN mutations in patients with Cowden disease : absence of clear genotype-phenotype correlations. Eur J Hum Genet EJHG. 1999;7:267-273.
  • [26] Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome : systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013 ; 105 : 1607-16.
  • [27] Chakrabarti S. Cronkhite-Canada Syndrome (CCS)-A Rare Case Report. J Clin Diagn Res JCDR. 2015;9:OD08-09.
  • [28] Nakamura M., Kobashikawa K., Tamura J. Cronkhite-Canada syndrome. Intern Med Tokyo Jpn. 2009;48:1561-1562.
  • [29] Sweetser S., Ahlquist D.A., Osborn N.K. Clinicopathologic features and treatment outcomes in Cronkhite-Canada syndrome : support for autoimmunity. Dig Dis Sci. 2012;57:496-502.